IL130715A - Form i of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoro-methyl-1,4-dihydro-2h-3,1-benzoxazin-2-one and a process for preparing the crystalline form of said compound - Google Patents

Form i of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoro-methyl-1,4-dihydro-2h-3,1-benzoxazin-2-one and a process for preparing the crystalline form of said compound

Info

Publication number
IL130715A
IL130715A IL13071598A IL13071598A IL130715A IL 130715 A IL130715 A IL 130715A IL 13071598 A IL13071598 A IL 13071598A IL 13071598 A IL13071598 A IL 13071598A IL 130715 A IL130715 A IL 130715A
Authority
IL
Israel
Prior art keywords
benzoxazin
dihydro
chloro
cyclopropylethynyl
trifluoro
Prior art date
Application number
IL13071598A
Other languages
English (en)
Other versions
IL130715A0 (en
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL130715(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9706046.1A external-priority patent/GB9706046D0/en
Priority claimed from GBGB9709348.8A external-priority patent/GB9709348D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL130715A0 publication Critical patent/IL130715A0/xx
Publication of IL130715A publication Critical patent/IL130715A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13071598A 1997-02-05 1998-02-02 Form i of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoro-methyl-1,4-dihydro-2h-3,1-benzoxazin-2-one and a process for preparing the crystalline form of said compound IL130715A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3738597P 1997-02-05 1997-02-05
GBGB9706046.1A GB9706046D0 (en) 1997-03-24 1997-03-24 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US4280797P 1997-04-08 1997-04-08
GBGB9709348.8A GB9709348D0 (en) 1997-05-07 1997-05-07 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
PCT/US1998/001999 WO1998033782A1 (en) 1997-02-05 1998-02-02 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Publications (2)

Publication Number Publication Date
IL130715A0 IL130715A0 (en) 2000-06-01
IL130715A true IL130715A (en) 2003-07-31

Family

ID=27451618

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13071598A IL130715A (en) 1997-02-05 1998-02-02 Form i of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoro-methyl-1,4-dihydro-2h-3,1-benzoxazin-2-one and a process for preparing the crystalline form of said compound

Country Status (18)

Country Link
EP (1) EP0975609B1 (cs)
JP (6) JP3418626B2 (cs)
KR (1) KR100573192B1 (cs)
CN (2) CN1191242C (cs)
AT (1) ATE486065T1 (cs)
AU (1) AU738545C (cs)
CA (1) CA2279198C (cs)
CZ (2) CZ297535B6 (cs)
DE (1) DE69841972D1 (cs)
EA (1) EA001805B1 (cs)
EE (1) EE03827B1 (cs)
HU (1) HU229087B1 (cs)
IL (1) IL130715A (cs)
NO (1) NO320128B1 (cs)
NZ (1) NZ336510A (cs)
PL (1) PL197740B1 (cs)
SK (1) SK284935B6 (cs)
WO (1) WO1998033782A1 (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229087B1 (en) * 1997-02-05 2013-07-29 Merck Sharp & Dohme Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US6015926A (en) * 1997-05-16 2000-01-18 Merck & Co., Inc. Efficient enantioselective addition reaction using an organozinc reagent
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US20060235008A1 (en) * 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009087679A2 (en) * 2007-12-24 2009-07-16 Matrix Laboratories Limited Process for preparing polymorphic forms of (s)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120289468A (zh) 2015-10-16 2025-07-11 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN114195761B (zh) * 2021-12-23 2023-04-14 浙江普洛家园药业有限公司 一种高纯度西他沙星3/2水合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
HU229087B1 (en) * 1997-02-05 2013-07-29 Merck Sharp & Dohme Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
EE9900446A (et) * 1997-04-07 2000-04-17 Dupont Pharmaceuticals Company Bensoksasinoonide asümmeetriline sünteesimine uute vaheühendite kaudu

Also Published As

Publication number Publication date
CA2279198A1 (en) 1998-08-06
PL197740B1 (pl) 2008-04-30
KR100573192B1 (ko) 2006-04-24
JP5295190B2 (ja) 2013-09-18
HUP0001313A3 (en) 2002-12-28
EE9900341A (et) 2000-02-15
SK284935B6 (sk) 2006-02-02
CZ276599A3 (cs) 2000-02-16
CA2279198C (en) 2009-04-14
PL334478A1 (en) 2000-02-28
CN1385425A (zh) 2002-12-18
CN1073991C (zh) 2001-10-31
JP6126172B2 (ja) 2017-05-10
NZ336510A (en) 2001-04-27
AU738545B2 (en) 2001-09-20
AU738545C (en) 2004-06-17
NO993779L (no) 1999-10-05
ATE486065T1 (de) 2010-11-15
CN1191242C (zh) 2005-03-02
JP3418626B2 (ja) 2003-06-23
JP2011006472A (ja) 2011-01-13
JP2003040874A (ja) 2003-02-13
EA001805B1 (ru) 2001-08-27
HU229087B1 (en) 2013-07-29
JP2015205914A (ja) 2015-11-19
CZ304186B6 (cs) 2013-12-11
EP0975609A4 (en) 2001-02-21
AU6263298A (en) 1998-08-25
NO993779D0 (no) 1999-08-04
EP0975609A1 (en) 2000-02-02
JP2017061575A (ja) 2017-03-30
NO320128B1 (no) 2005-10-31
SK105599A3 (en) 2000-05-16
CN1246113A (zh) 2000-03-01
JP2000507972A (ja) 2000-06-27
HUP0001313A2 (hu) 2000-10-28
EP0975609B1 (en) 2010-10-27
IL130715A0 (en) 2000-06-01
CZ297535B6 (cs) 2007-01-03
JP2013139484A (ja) 2013-07-18
EE03827B1 (et) 2002-08-15
DE69841972D1 (de) 2010-12-09
WO1998033782A1 (en) 1998-08-06
EA199900720A1 (ru) 2000-04-24
KR20000070735A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
IL130715A (en) Form i of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoro-methyl-1,4-dihydro-2h-3,1-benzoxazin-2-one and a process for preparing the crystalline form of said compound
ATE510798T1 (de) Verfahren zur herstellung eines kristallinen, zeolithischen feststoffs
DE60009326D1 (de) Verfahren zur herstellung von silicoaluminophosphat-molekularsieben
DE69433010D1 (de) Verfahren zur darstellung von oligonukleotiden
CA2135138A1 (en) Method for producing formic acid or its derivatives
GB9814882D0 (en) Process
DE50211882D1 (de) Protonenleitfähige Membranen/Schichten und Verfahren zu deren Herstellung
CA2347515A1 (en) Crystallization of doxorubicin hydrochloride
MY134189A (en) Process for preparing crystalline form i of cabergoline
CA2319788A1 (en) A method of modifying a crystalline molecular sieve material
MY122309A (en) Method of producing semiconductor wafer
JPS5271446A (en) Novel method for preparing 3',4'-dideoxykanamycin b
DK1334962T3 (da) Fremgangsmåder til fremstilling af acylphenylalanin
EP0992503A4 (en) METHOD FOR PRODUCING AN ISOOXAZOLIDINDIONED COMPOUND
JPS51151391A (en) Process for preparing l-sulfur- containing amino acids
DE59508152D1 (de) Verfahren zur herstellung fester, freifliessender wasserlöslicher salze von aryloxi-c 1-c 4-alkancarbonsäuren
ES2152571T3 (es) Procedimiento para la preparacion de dioxoazabiciclohexanos.
AU6451794A (en) Process for preparing crystalline beta-lactam monohydrate
AU668458B2 (en) Method of obtaining a physically stable crystalline y-modification of paraminobenzene sulphanilamide
TR200100082T2 (tr) Klavulanik asit tuz ve esterlerinin hazırlanması için geliştirilmiş yöntem
DE50004982D1 (de) Verfahren zur herstellung von phytosterinen
JPS5469957A (en) Production of semiconductor device
JPS5318359A (en) System for restarting information processing from beginning when abnormal state occurs during information processing.
KR940005606A (ko) 순수한 트리옥산의 제조 방법
AU3566795A (en) Process for preparing d,l-aspartic acid from ammonium salts of the maleic acid

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired